Global Blood Therapeutics is focusing on developing novel medicines to revolutionize the treatment of chronic blood-based diseases for which the biology is well understood. As one of the largest and most accessible organs, blood is a rich source of biologically and clinically validated targets.
Global Blood Therapeutics aims to transform the treatment paradigm for severe diseases for which there are currently no cures and only extremely limited therapeutic options. These rare genetic diseases affect defined patient populations in the United States and large patient populations worldwide.
Through its SHAPE Platform, Global Blood Therapeutics is discovering and developing novel, oral medicines designed to change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits.
Global Blood Therapeutics is rapidly advancing its pipeline of preclinical programs in several monogenic blood disorders.